[{"from": "human", "value": "Provide a description of this molecule. [C][C][C][=C][N][Branch1][#Branch2][C][=Branch1][C][=O][N][C][Ring1][#Branch1][=O][C@H1][C][C@@H1][Branch1][=Branch2][C@H1][Branch1][Ring2][O][Ring1][Branch1][C][O][O]"}, {"from": "gpt", "value": "The molecule is a deoxythymidine analog with activity against herpes simplex virus. It is a potent and selective inhibitor of herpes simplex virus type 1 and 2. The obtained product is an antiviral ointment. The activity of edoxudine against herpes simplex virus was first recognized in 1967. It was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus. It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998."}]